Status:

COMPLETED

Nijmegen Antihypertensive Management Improvement Study

Lead Sponsor:

Radboud University Medical Center

Conditions:

Primary Hypertension

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

High blood pressure is an important risk factor for diseases of heart and blood vessels like myocardial infarction and stroke. Many patients are not treated to target blood pressures, even though good...

Detailed Description

Population-wide elimination of hypertension would reduce the incidence of all stroke, MI and heart failure with 30 to 50% and contribute to a reduction of between 25 to 50% of the total mortality rela...

Eligibility Criteria

Inclusion

  • Age 18-65 years with newly diagnosed hypertension in general practice
  • hypertension is defined as either \> 140 mm Hg systolic or \> 90 mm Hg diastolic on three separate days.

Exclusion

  • History of cardiovascular disease (transient ischemic attack (TIA), stroke, myocardial infarction (MI), peripheral arterial disease (PAD), atrial fibrillation (AF), angina pectoris (AP), Diabetes Mellitus)
  • Unable to understand and/or speak Dutch
  • Severe hypertension (\> 200/120 mmHg)
  • Irregular pulse
  • Use of antihypertensive medication
  • Contraindication to one of the trial drugs
  • Serious suspicion on secondary hypertension

Key Trial Info

Start Date :

August 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2011

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT00457483

Start Date

August 1 2007

End Date

March 1 2011

Last Update

February 14 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Nijmegen monitoring project coordinated from Nijmegen

Nijmegen, Netherlands